Dewpoint Therapeutics Taps Ex-Sanofi Executive Ameet Nathwani as CEO

Ameet Nathwani has been appointed CEO of Dewpoint Therapeutics. He is also joining the Boston company’s board of directors. Earlier this year, Nathwani left his chief medical officer and chief digital officer roles at Sanofi (NYSE: [[ticker:SNY]]) as part of an executive team shakeup. His experience also includes 12 years at Novartis (NYSE: [[ticker:NVS]]) in a number of senior roles. Dewpoint is developing drugs that target components of cells called biomolecular condensates. The biotech has research and development partnerships with Bayer and Merck (NYSE: [[ticker:MRK]]).

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.